NAPSRx News: Endo plans to expand generics business by acquiring Par Pharmaceuticals

May 19, 2015 - PRLog -- In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.  The Board of Directors and management teams from both companies unanimously approved the transaction consisting of a purchase price of 18 million shares valued at approximately $1.55 billion plus $6.50 billion cash consideration to Par shareholders. This acquisition will now put Endo, a specialty pharmaceutical firm ahead of the game as the company will now gain access to a fast growing generics business among the top five in the United States as measured by sales.

"Our generics business, Qualitest, continues to be an extremely attractive and effective growth driver for Endo. This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A," said Rajiv De Silva, President and CEO of Endo.

"This is an exciting time of growth and opportunity in the generics and specialty pharmaceutical arenas. Par Pharmaceutical is committed to significantly expanding our scope, capacity and capabilities to realize the maximum value of our rich and diversified product portfolio and R&D pipeline. We believe our combination with Endo best positions us to do so," said Mr. Campanelli, CEO of Par Pharmaceutical. "We share Endo's goal of developing and commercializing generic drugs in areas of greatest revenue potential, complex formulations and longer life cycles. I look forward to joining the Endo team and working together to achieve that goal."

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

Industry analysts predict this transaction will drive long-term double-digit revenue growth for Endo. This will without a doubt bolster the need for both certified and qualified individuals to promote the company's diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they prefer individuals that are industry trained and have the background to promote their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.